Jan Hillert's research group - our research
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system affecting more than two million people world-wide. MS is the second most common cause of neurological disability in young adults. The disease progression varies between patients but often causes different degrees of disability.
Neuroepidemiology with focus on multiple sclerosis
In the MS epidemiology research group, we use data from the Swedish MS registry on its own or linked to data from public databases such as Statistics Sweden, National Board of Health and Welfare and Swedish Social Insurance Agency in order to perform epidemiological studies related to MS. Access to these large data collections allows as to conduct research projects into MS outcomes with the aim of describing how MS patients fare over time as regards disease progression, treatment regimens and socioeconomic outcomes. Our studies will hopefully contribute to increased knowledge of factors influencing MS disease and socioeconomic burden of MS with the ultimate ambition of providing the basis for an improved and cost effective healthcare for MS patients.
Our research group consists of molecular biologists, epidemiologists and neurologists.
- Basic epidemiology
Incidence and prevalence of MS in Sweden, MS geographical distribution and changes over time in incidence and prevalence of MS
- Treatment studies (pharmacoepidemiology)
Patterns of treatment initiation, switch, escalation and discontinuation, types of treatment, adverse effects and treatment efficacy
- Health economy and societal consequences of MS
Cost of MS, sickness absence, disability pension, earnings
- Clinical course of MS
Progression of disability and impairment in different types of MS, investigations on causes and course of pediatric MS, and factors influencing disease progression
Research Group Leader
Accurate classification of secondary progression in multiple sclerosis using a decision tree.
Ramanujam R, Zhu F, Fink K, Karrenbauer VD, Lorscheider J, Benkert P, Kingwell E, Tremlett H, Hillert J, Manouchehrinia A,
Mult Scler 2021 07;27(8):1240-1249
A multiple sclerosis disease progression measure based on cumulative disability.
Manouchehrinia A, Kingwell E, Zhu F, Tremlett H, Hillert J, Ramanujam R
Mult Scler 2021 Jan;():1352458520988632
Cerebrospinal fluid oligoclonal immunoglobulin gamma bands and long-term disability progression in multiple sclerosis: a retrospective cohort study.
Karrenbauer VD, Bedri SK, Hillert J, Manouchehrinia A
Sci Rep 2021 07;11(1):14987
Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network.
Iaffaldano P, Lucisano G, Butzkueven H, Hillert J, Hyde R, Koch-Henriksen N, Magyari M, Pellegrini F, Spelman T, Sørensen PS, Vukusic S, Trojano M
Mult Scler 2021 Sep;27(10):1543-1555
Factors affecting the risk of relapsing-onset and progressive-onset multiple sclerosis.
Hedström AK, Hillert J, Olsson T, Alfredsson L
J Neurol Neurosurg Psychiatry 2021 Oct;92(10):1096-1102
Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry.
Spelman T, Forsberg L, McKay K, Glaser A, Hillert J
Mult Scler 2021 Jul;():13524585211026272
Long-term Socioeconomic Outcomes Associated With Pediatric-Onset Multiple Sclerosis.
McKay KA, Friberg E, Razaz N, Alexanderson K, Hillert J
JAMA Neurol 2021 Apr;78(4):478-482
Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies.
Spelman T, Magyari M, Piehl F, Svenningsson A, Rasmussen PV, Kant M, Sellebjerg F, Joensen H, Hillert J, Lycke J
JAMA Neurol 2021 Aug;():
Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network.
Hillert J, Magyari M, Soelberg Sørensen P, Butzkueven H, Van Der Welt A, Vukusic S, Trojano M, Iaffaldano P, Pellegrini F, Hyde R, Stawiarz L, Manouchehrinia A, Spelman T
Front Neurol 2021 ;12():647811
Determinants of quality of life in pediatric- and adult-onset multiple sclerosis.
McKay KA, Ernstsson O, Manouchehrinia A, Olsson T, Hillert J
Neurology 2020 03;94(9):e932-e941
Importance of early treatment decisions on future income of multiple sclerosis patients.
Kavaliunas A, Manouchehrinia A, Gyllensten H, Alexanderson K, Hillert J
Mult Scler J Exp Transl Clin ;6(4):2055217320959116
Long-Term Consequences of High Titer Neutralizing Antibodies to Interferon-β in Multiple Sclerosis.
Dunn N, Fogdell-Hahn A, Hillert J, Spelman T
Front Immunol 2020 ;11():583560
Socioeconomic status and multiple sclerosis outcome.
Nat Rev Neurol 2020 04;16(4):191-192
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.
He A, Merkel B, Brown JWL, Zhovits Ryerson L, Kister I, Malpas CB, Sharmin S, Horakova D, Kubala Havrdova E, Spelman T, Izquierdo G, Eichau S, Trojano M, Lugaresi A, Hupperts R, Sola P, Ferraro D, Lycke J, Grand'Maison F, Prat A, Girard M, Duquette P, Larochelle C, Svenningsson A, Petersen T, Grammond P, Granella F, Van Pesch V, Bergamaschi R, McGuigan C, Coles A, Hillert J, Piehl F, Butzkueven H, Kalincik T,
Lancet Neurol 2020 04;19(4):307-316
Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.
Beiki O, Frumento P, Bottai M, Manouchehrinia A, Hillert J
JAMA Neurol 2019 06;76(6):665-671